Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Media
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsShortsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Media
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Marleen Meyers, MD

Advertisement

Articles by Marleen Meyers, MD

TIP66 Feasibility of the THRIVE Wellness Program for Young Breast Cancer Survivors: A Multicenter Pilot Trial

ByShivali Devjani,Amanda Bontempo,Elizabeth A. Comen, MD,Danielle Seidman,Elena Katz,Nina D'Abreo,Marleen Meyers, MD,Wanqing Iris Zhi,Naomi Ko
June 15th 2026

This randomized multicenter pilot trial assesses feasibility of the THRIVE Wellness Program, a 6-week lifestyle intervention for young breast cancer survivors aged 40 years or younger.

Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer

ByMarleen Meyers, MD
June 17th 2019

Cancer Network spoke with Marleen Meyers, MD, about evidence on low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ.

Advertisement

Latest Updated Articles

  • Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
    Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer

    June 17th 2019



Advertisement
Advertisement

Trending on CancerNetwork

1

FDA Accepts NDA for Daraxonrasib in Pretreated Metastatic Pancreatic Cancer

2

RASolute 302 and the Future of Pancreatic Cancer Treatment: Paul Oberstein, MD, on the KRAS Breakthrough

3

Mapping the Full CAR T-Cell Journey in DLBCL From Referral to Survivorship

4

Balancing Oncologic Outcomes With Patient Priorities in Prostate Cancer Care

5

Optimizing Surveillance Protocols After Focal Therapy for Prostate Cancer

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us